These Are the Stocks With the Largest Changes in Short Interest in July - GS
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Arcadia Biosciences (RKDA)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
Summit Therapeutics Analyst Ratings
Express News | Summit Therapeutics PLC : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $16
Express News | Two Ivonescimab (Pd-1/Vegf) Results Including Phase 3 Monotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment for Pd-L1 Positive Nsclc to Be Presented at Wclc 2024
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Summit Therapeutics Shatres Are Trading Higher After the Company Reported Better-than-expected Q2 Adjusted EPS Results
Express News | Summit Therapeutics Inc Files for Resale of up to 22.22 Mln Shares by the Selling Stockholders - SEC Filing
Summit Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Summit Therapeutics: Have Sufficient Cash to Fund Operations Into Q4 of 2025
Earnings Flash (SMMT) SUMMIT THERAPEUTICS Reports Q2 Loss $-0.05 Per Share, Vs. Street Est of Loss $-0.06 Per Share
Express News | Summit Therapeutics Q2 Operating Income USD -59.6 Million
Express News | Summit Therapeutics Q2 Operating Expenses USD 59.8 Million
Express News | Summit Therapeutics Q2 Net Income USD -60.4 Million
Express News | Summit Therapeutics Q2 EPS USD -0.09
Express News | Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
Express News | Summit Therapeutics up 4.8% Premarket Ahead of Q2 Results
Summit Therapeutics Q2 2024 Earnings Preview
Unusual Options Activity: MMM, TEVA and Others Attract Market Bets, MMM V/OI Ratio Reaches 114.2